Merck price target raised to $112 from $109 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck (MRK) to $112 from $109 and keeps an Equal Weight rating on the shares. The company reported a Q1 topline beat driven by the timing of Keytruda U.S. purchases, and the midpoint of guidance was raised, the analyst tells investors in a research note. The firm added that pipeline execution and capital deployment remain the key for the stock.